<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3775">
  <stage>Registered</stage>
  <submitdate>30/10/2012</submitdate>
  <approvaldate>30/10/2012</approvaldate>
  <nctid>NCT01772017</nctid>
  <trial_identification>
    <studytitle>A Trial to Evaluate a Device for the Treatment of OSA and Snoring</studytitle>
    <scientifictitle>A Multi Center, Open Label Study to Evaluate a Tongue Advancement Retainer Device in the Treatment of Subjects With Obstructive Sleep Apnea and Snoring (OPEN Trial)</scientifictitle>
    <utrn />
    <trialacronym>OPEN</trialacronym>
    <secondaryid>OPEN-002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obstructive Sleep Apnea</healthcondition>
    <healthcondition>Snoring</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Sleep apnoea</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Tongue Advancement Retainer Device

Experimental: Device Treatment - Tongue Advancement Retainer Device


Treatment: devices: Tongue Advancement Retainer Device
Tongue Advancement Retainer Device

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary Safety Endpoint - The safety of the device will be measured through recorded observations of adverse events. - Safety endpoint will be measured throughout the duration of the study.</outcome>
      <timepoint>Approximately 6 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Primary Efficacy Endpoint - Change in the overall Apnea Hypopnea Index (AHI) from the PSG at baseline and end of treatment phase. - Efficacy Endpoint will be measured at baseline and at end of treatment.</outcome>
      <timepoint>Approximately 6 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-   Aged 18-65

               -  AHI greater than or equal to 10 but less than or equal to 60 (&lt;10 AHI &lt;60/hr)

               -  Complete set of lower anterior incisors with no evidence of periodontal disease
                  or mobility and the ability to floss between teeth

        Additionally subjects will in the screening phase must:

          -  Tolerate the device when being fitted

          -  Used the device for &gt;4 hours on at least two consecutive nights during the screening
             period.

          -  Be able to reliably demonstrate proper installation of the device after fitting.

          -  Be willing to trial the device for a 4 week period</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-   Central sleep apnea events &gt;10% of the total events

               -  Evidence of Cheyne stokes breathing

               -  Currently on treatment for OSA or OSA treatment discontinued less than 3 months
                  prior.

               -  Currently on regular treatment with prescription hypnosedatives or prescription
                  stimulants

               -  Very severe OSA, defined as AHI&gt;60/hour and/or minimum oxygen saturation &lt;75%

               -  Need for immediate initiation of treatment as assessed by physician (e.g.
                  Excessive sleepiness posing driving risk)

               -  Previous surgery to treat OSA (other than nasal surgery)

               -  Evidence of periodontal disease or tooth mobility

               -  Severe nasal obstruction or enlarged tonsils based on clinical assessment

               -  Unstable cardiovascular disease (untreated hypertension acceptable).

               -  Inability to tolerate oral device due to oral condition or claustrophobia as
                  determined by the study investigator

               -  Pregnant/Breast Feeding

               -  Any known factor or disease that might interfere with treatment compliance, study
                  conduct or interpretation of the results such as co-existent other sleep
                  disorder, psychiatric disease, history of non compliance to medical regimens, or
                  unwillingness to comply with study requirements.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>15</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Royal North Shore Hospital - St. Leonards</hospital>
    <postcode>2065 - St. Leonards</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sleepy, Inc</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To evaluate the safety and efficacy of the Tongue Advancement Retainer Device in treating
      subjects with Obstructive Sleep Apnea (OSA) and snoring.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01772017</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Brian Weeks, MD</name>
      <address>Senta Clinic</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>